In this study, we tested whether bimekizumab helps people with a skin disease called hidradenitis suppurativa.

Study in progress
This research study is no longer accepting participants. The following details are for information only.

About this study

Enrolment to this study has closed.

Hidradenitis suppurativa (HS) is a chronic inflammatory debilitating skin condition characterised by painful, deep skin lesions commonly under the arms or in the groin area.  It can be treated with topical treatments on the skin, tablets, injections or infusions.

The investigational drug for this study is called bimkizumab and it was given as an injection into the skin to participants. 

The purpose of the research project was to measure how safe and effective this medication is in treating participants with HS. Prior research studies in humans have shown that this medication may help control the immune system that is responsible for the signs and symptoms of HS and help achieve disease improvement.

More information about the study

NCT04901195 Identifier
Person handling test tubes for research


All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.

This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.

The RMH Clinical Trials Centre
Clinical Trials Centre

The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.

The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.